Please login to the form below

Not currently logged in


This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... NICE already recommends Perjeta with trastuzumab

Latest news

More from news
Approximately 17 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...